Bristol-Myers Squibb Company EV/EBITDA

Data as of June 01, 2026

How It's Calculated

What This Means

Bristol-Myers Squibb Company's EV/EBITDA of 8.1 is on the lower side versus many large-cap peers — context still depends on growth and leverage.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMY) operates in the Healthcare sector, specifically in Drug Manufacturers - General. With a market capitalization of about $116.77B, it ranks as a large-cap stock — a major established company.

Shares recently traded near $57.18, within a 52-week range of $42.52 to $62.89 (-9.1% from the high, +34.5% from the low). Beta of 0.26 indicates relatively lower volatility versus the market.

Trailing profit margin is about 15.0%, signaling a solid profit margin for its industry.

Understanding This Metric

EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Bristol-Myers Squibb Company, the ratio should be read with growth, capex needs, and cycle position in Healthcare. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.

Using This Number in Practice

Near 8.05x EV/EBITDA, Bristol-Myers Squibb Company (BMY) carries a mid-range EV/EBITDA multiple that investors often stack-rank within the sector. Enterprise value of about $152.74B and EBITDA near $18.97B form the ratio — adjust for one-time items before treating the headline multiple as comparable.

Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the BMY metrics hub for related valuation pages.

Sector Comparison

Among Healthcare names on our S&P 100 coverage, Bristol-Myers Squibb Company's EV/EBITDA of 8.05 can be compared with peers such as LLY (28.26), JNJ (16.76), UNH (18.61). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Healthcare stocks.

Key Takeaways

• BMY is grouped in the Healthcare sector for peer comparisons.
• Recent beta of 0.26 suggests lower-than-market price sensitivity.
• Trailing profit margin of 15.0% provides context for how much earnings support the headline multiple.

Related Tools & Guides

Explore calculators and guides connected to this metric, or view all metrics for BMY.

Other BMY Metrics

Frequently Asked Questions